SS-31 Peptide Targets Mitochondria to Fight Both Diabetes and Alzheimer's Disease
The mitochondria-targeted peptide SS-31 shows superior therapeutic potential over traditional antioxidants like vitamin E by directly restoring mitochondrial function in both diabetes and Alzheimer's disease.
Quick Facts
What This Study Found
SS-31 peptide targets mitochondria directly, inhibiting oxidative stress and restoring mitochondrial function with greater therapeutic potential than traditional antioxidants like vitamin E in models of diabetes and Alzheimer's disease.
Key Numbers
SS-31 concentrates in mitochondria; inhibits reactive oxygen species; superior to vitamin E in models
How They Did This
Narrative review summarizing pathophysiological evidence of mitochondrial dysfunction in diabetes and Alzheimer's disease, and the beneficial effects of SS-31 peptide compared to conventional antioxidants.
Why This Research Matters
Diabetes and Alzheimer's are two of the most common chronic diseases with inadequate treatments. A peptide that addresses their shared mitochondrial dysfunction could offer a fundamentally different therapeutic approach from current drugs.
The Bigger Picture
Mitochondria-targeted therapeutics represent a paradigm shift from general antioxidant supplementation. SS-31 (elamipretide) is already in clinical trials for other conditions involving mitochondrial dysfunction, and its potential application to diabetes and Alzheimer's could significantly expand its therapeutic reach.
What This Study Doesn't Tell Us
Review article with no new experimental data. Most SS-31 evidence for diabetes and Alzheimer's comes from preclinical models. Clinical trial data for these specific conditions is limited. The relationship between mitochondrial dysfunction and disease causation is still being clarified.
Questions This Raises
- ?Can SS-31 slow or prevent Alzheimer's progression in human clinical trials?
- ?Would SS-31 work best as a standalone treatment or combined with existing diabetes medications?
- ?Are there long-term safety concerns with chronic mitochondria-targeted peptide therapy?
Trust & Context
- Key Stat:
- Superior to vitamin E SS-31 concentrates inside mitochondria to fight oxidative stress at the source, outperforming traditional antioxidants that lack mitochondrial targeting
- Evidence Grade:
- Not applicable (narrative review). Based primarily on preclinical evidence with limited clinical trial data for diabetes and Alzheimer's specifically.
- Study Age:
- Published in 2021. SS-31 (elamipretide) clinical development has continued for various mitochondrial conditions.
- Original Title:
- Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in Diabetes Mellitus and Alzheimer's disease.
- Published In:
- Pharmacological research, 171, 105783 (2021)
- Authors:
- Ding, Xiao-Wen, Robinson, Megan, Li, Rongzi, Aldhowayan, Hadeel, Geetha, Thangiah, Babu, Jeganathan Ramesh
- Database ID:
- RPEP-05347
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is SS-31 and how is it different from regular antioxidants?
SS-31 (also called elamipretide) is a small peptide designed to concentrate specifically inside mitochondria. Unlike vitamin E or other general antioxidants that spread throughout the body, SS-31 goes directly where oxidative damage originates, making it more effective at restoring mitochondrial function.
How are diabetes and Alzheimer's disease connected?
Both conditions involve mitochondrial dysfunction and excessive production of reactive oxygen species. Damaged mitochondria impair energy production in brain cells (contributing to Alzheimer's) and disrupt glucose regulation (contributing to diabetes). Having one condition also increases risk for the other.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05347APA
Ding, Xiao-Wen; Robinson, Megan; Li, Rongzi; Aldhowayan, Hadeel; Geetha, Thangiah; Babu, Jeganathan Ramesh. (2021). Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in Diabetes Mellitus and Alzheimer's disease.. Pharmacological research, 171, 105783. https://doi.org/10.1016/j.phrs.2021.105783
MLA
Ding, Xiao-Wen, et al. "Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in Diabetes Mellitus and Alzheimer's disease.." Pharmacological research, 2021. https://doi.org/10.1016/j.phrs.2021.105783
RethinkPeptides
RethinkPeptides Research Database. "Mitochondrial dysfunction and beneficial effects of mitochon..." RPEP-05347. Retrieved from https://rethinkpeptides.com/research/ding-2021-mitochondrial-dysfunction-and-beneficial
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.